GlassScriptPhysician profile
Jason Richard Kolkmeier
NPI 1093815516
$4,548.65
in general payments reported to CMS, 2019-2025
45 companies · $720 in 2025
The $720 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $815 · 2022: $783 · 2023: $1,090 · 2024: $1,140 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.72 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $323.56 | 2024 | Qelbree |
| Pfizer INC. | $234.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.77 | 2021-2025 | Farxiga, Andexxa, Bevespi Aerosphere |
| Axsome Therapeutics, INC. | $184.14 | 2022-2025 | Auvelity |
| Lilly USA, LLC | $179.36 | 2021-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.87 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $159.17 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $146.09 | 2022-2023 | Fanapt, Hetlioz |
| Novo Nordisk INC | $138.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $99.76 | 2021-2024 | Rexulti |
| Amgen INC. | $86.53 | 2023-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $78.44 | 2023-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $77.74 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.07 | 2022-2025 | Caplyta |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kolkmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.